AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05796284 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breast pressure relief intervention at the end of pregnancy
Description: When teaching pregnant women, the researchers will use tablet computers and models to explain the operation of breast combing and acupressure one-on-one, and use the model to demonstrate. Emphasis on breast grooming during pregnancy, twice a day, once in the morning and evening, 5 minutes on one breast each time, 10 minutes on both sides; strengthen breast grooming and acupressure after delivery. The first breast combing, 5 minutes on one breast each time, and 10 minutes on both sides 4 to 6 times a day. After combing, according to expert advice, massage the 6 acupoints around the breast for 5-10 seconds, and then use hand expressing or breastfeeding to discharge the milk .
Study NCT05796284 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine care
Description: Cases in the routine care group received routine prenatal care and guidance during weekly outpatient checkups, and routine postpartum care and guidance after delivery.
Study NCT06575699 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rectus sheath block
Description: bilateral rectus sheath block under ultrasound guidance using 133 mg liposomal bupivacaine and 20 ml bupivacaine 0.25% per side deposited between the rectus abdomens muscle and the posterior rectus sheath.
Study NCT06575699 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic Epidural Analgesia
Description: Low thoracic Epidural Analgesia.
Study NCT05796284 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine care
Description: Cases in the routine care group received routine prenatal care and guidance during weekly outpatient checkups, and routine postpartum care and guidance after delivery.
Study NCT06575699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: 133 mg liposomal bupivacaine per side for rectus sheath block
Study NCT06575699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride
Description: 20 mL bupivacaine 0.25% per side for rectus sheath block
Study NCT06252051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trivalent Influenza Vaccine
Description: We divided the participants into three groups: one comprising healthy individuals, another consisting of those with type 2 diabetes mellitus (T2DM), and the last group comprising individuals with T2DM and chronic kidney disease (CKD). All participants will receive a trivalent influenza vaccine, and various parameters will be observed.
Study NCT06575699 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine-Hydromorphone Cassette
Description: Bupivacaine 0.625% with hydromorphone 10 mcg/ml for the epidural solution
Study NCT04964609 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EmbracePlus
Description: A device intended for use by researchers and healthcare professionals for continuous collection of physiological parameters in home and healthcare settings.~Parallel blood gas analysis to determine oxyhemoglobin saturation (SaO2) using an ABL-90 multi-wavelength oximeter.
Study NCT05455554 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Flowmet-D
Description: Flowmet-D is a non-invasive device that measures blood flow.
Study NCT05483296 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low light condition
Description: During the Dim light condition, the three-hour afternoon light exposure at the participants' eye level will be dim (\<5 lx melanopic EDI). In the 4.5-hour evening light exposure, this will constitute a light intensity of \~100 lx melanopic EDI at the participants' eye level.
Study NCT05483296 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate light condition
Description: During the Moderate light condition, the three-hour afternoon light exposure at the participants' eye level will be dim (\~100 lx melanopic EDI). In the 4.5-hour evening light exposure, this will constitute a light intensity of \~100 lx melanopic EDI at the participants' eye level.
Study NCT05483296 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High light condition
Description: During the High light condition, the three-hour afternoon light exposure at the participants' eye level will be dim (>1000 lx melanopic EDI). In the 4.5-hour evening light exposure, this will constitute a light intensity of \~100 lx melanopic EDI at the participants' eye level.
Study NCT05455554 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ABI
Description: ABI is the ratio of the systolic blood pressure measured at the ankle to that measured at the brachial artery and is considered the gold standard for the diagnosis of peripheral artery disease.
Study NCT05670223 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fit&Strong Exercise Program
Description: The Fit and Strong! Program (F\&S!) is an exercise program for older adults developed by a study consultant, Dr. Susan Hughes, with funding from the National Institute of Aging. It is tailored for the unique needs of older, underserved adults and targets modifiable factors depicted by the socioecological model is necessary. The F\&S! exercise program assists older adults to improve strength and functioning.
Study NCT04999306 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: one weekly session during 6 weeks (6 sessions of 30min/1 hour).
Study NCT04999306 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT
Description: one weekly session during 6 weeks (6 sessions of 1 hour).
Study NCT04799548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transcatheter Arterial Chemoembolization
Description: Patients will sequentially receive one cycle TACE (3 weeks), one cycle SOX regimen (3 weeks), one cycle TACE (3 weeks) and one cycle SOX (3 weeks) regimen, a total of 12-week neoadjuvant therapy.~TACE cycle: Day 1: trans-femorally performed with infusion of oxaliplatin (85 mg/m2) into tumor blood vessels. Then, Embosphere® Microspheres (300-500 μm) will be injected for embolism. Day 1-14: Oral Tegafur Gimeracil Oteracil Potassium Capsule 40-60 mg bid.~SOX cycle: Day 1: Oxaliplatin 130mg/m2 intravenous. Day 1-14: Oral Tegafur gimeracil oteracil potassium capsule 40-60 mg bid.
Study NCT04799548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: PD-1 antibody Tislelizumab will be administrated by 200mg, ivgtt, q3w throughout 12-week neoadjuvant treatment.
Study NCT05659862 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digitally assisted behavioral physical activity intervention
Description: Digitally Assisted Behavioral Physical Activity Intervention Each week, the step count target will be renewed and an average of 20 minutes of phone calls will be made, including motivational interviews guided by Social Cognitive Theory. Motivational interviews will last 8 weeks.~Outcome Expectations - Informing about the positive results when the physical activity level is increased and the dose-effect relationship Self Efficacy - Individuals' previous physical activity/exercise experiences will be evaluated and discussed.~Social Support - A WhatsApp group will be created. Self Regulation - Self-monitoring ; Goal setting; Feedback, Self-reward
Study NCT05659862 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Patient Education~* Definition of fibromyalgia syndrome~* Symptoms of fibromyalgia syndrome~* Exercise and physical activity~* Recommendations to improve the quality of life~* Sleep quality and sleep hygiene~* Pain management~* Fatigue and energy conservation techniques All patient education content will also be available on the website.
Study NCT05659862 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Patient Education~* Definition of fibromyalgia syndrome~* Symptoms of fibromyalgia syndrome~* Exercise and physical activity~* Recommendations to improve the quality of life~* Sleep quality and sleep hygiene~* Pain management~* Fatigue and energy conservation techniques All patient education content will also be available on the website.
Study NCT06568744 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention resuscitation
Description: In fluid responsive patients, fluid intolerance will be checked.~Lung Ultrasound (LUS): Anterior LUS with 4-point assessment at each hemithorax. Min:0 and a max:24. Low risk: \< 10; intermediate risk: 10-14 or delta of 2 points. High risk: >14, or an increase >4 from baseline.~VExUS: Low risk: Grade 0-1. Intermediate risk: 2. High risk: 3 E/e' ratio: Low risk: \<8. Intermediate risk: 8-13. High risk >14. Central venous pressure (CVP): Low risk \<12 mmHg. Intermediate risk: 12-15 mmHg or a delta of 3 mmHg. High risk > 15 mmHg or >5 mmHg increase after a fluid challenge.~In low-risk, a fluid challenge of 500 ml of balanced crystalloid will be performed in 30 minutes. If intermediate risk, a fluid challenge of 250 ml of balanced crystalloid in 30 minutes. If high-risk signals, alternative strategies (vasopressor and inodilator tests) will be deployed. After each challenge, peripheral perfusion, fluid responsiveness and intolerance will be re-assessed.
Study NCT06568744 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care resuscitation
Description: In fluid responsive patients, fluid challenges of 500 ml of balanced crystalloid will be performed in 30 minutes. After a fluid challenge, peripheral perfusion status and fluid responsiveness will be re-measured. If the patient persists with hypoperfusion, successive fluid challenges will be performed until hypoperfusion resolves or the patient becomes fluid unresponsive. If hypoperfusion signals persists and the patient becomes fluid unresponsive, alternative resuscitation interventions will be deployed, which include: 1) vasopressor titration to higher mean arterial pressure (MAP) targets in a MAP-test, and 2) addition of an inotrope to increase cardiac output in an inodilator test. If hypoperfusion fails to resolve, rescue therapies such as high-volume hemofiltration will be initiated.
Study NCT06187571 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CT+MWM
Description: The MWM technique was applied to the MWM group in addition to the CT. The MWM technique was applied in flexion, abduction, internal rotation, and external rotation directions. The MWM technique was performed with 3 sets of 10 repetitions.
Study NCT06187571 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CT
Description: Cold packs, electrotherapy modalities, scapular mobilization, stretching, and strengthening exercises were applied to the CT group.
Study NCT04851860 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: sublingual immunotherapy
Description: sublingual immunotherapy is the only disease modifying therapy preventing the evolution of AR to asthma
Study NCT05565235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: patients will receive intraoperative serratus block with bupivacaine
Description: no additives
Study NCT05565235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: serratus block with bupivacaine /magnesium
Description: magnesium added
Study NCT05565235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: serratus block with bupivacaine with nalbuphine
Description: nalbuphine added
Study NCT05214014 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Regulatory Т-cells
Description: Autologous Regulatory Т-cells obtained from CD4+CD25+ cells isolated from PBMC and cultured with the cocktail of cytokines and antibodies to induce proliferation of Tregs
Study NCT05214014 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment according to the clinical protocols
Description: Standard treatment of Systemic Sclerosis according to the clinical protocols
Study NCT05214014 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard treatment according to the clinical protocols
Description: Standard treatment of Systemic Sclerosis according to the clinical protocols
Study NCT06495437 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of extracellular vesicle preparation derived from Wharton's jelly mesenchymal stem cells.
Description: The trial protocol includes a 3-week screening period and a 12-week study period after enrollment. The specific trial protocol is detailed in the figure above. Cell-derived extracellular vesicle formulation will be administered at week 0, with central visits conducted during the administration period. Central visits will also be conducted at weeks 1, 4, and 12 post-administration, with a phone visit at week 8. The entire study will last for 12 weeks. Following the final follow-up visit, further observation of the intervention's effects and safety will continue for an additional 3 months. During this 3-month period, there will be no artificial intervention or restriction on the medication and biological methods for the participants in each group.
Study NCT04726475 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interoceptive Aversive Memory Reactivation
Description: In order to reactivate interoceptive aversive memory, participants will be asked to breathe a medical grade 35% CO2/65% O2 gas mixture which produces somatic perturbations. The 35% CO2 challenge is a widely used and safe symptom induction technique that has been utilized in our laboratory in several experiments. Participants will be informed that breathing the gas is safe, but that it will likely cause changes in their physical sensations. Participants will specifically be asked to breathe the gas mixture normally with their mouth open through an oxygen mask for 10 seconds.
Study NCT04726475 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interoceptive Aversive Memory Reactivation
Description: In order to reactivate interoceptive aversive memory, participants will be asked to breathe a medical grade 35% CO2/65% O2 gas mixture which produces somatic perturbations. The 35% CO2 challenge is a widely used and safe symptom induction technique that has been utilized in our laboratory in several experiments. Participants will be informed that breathing the gas is safe, but that it will likely cause changes in their physical sensations. Participants will specifically be asked to breathe the gas mixture normally with their mouth open through an oxygen mask for 10 seconds.
Study NCT04726475 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Interoceptive Aversive Memory Reactivation
Description: In order to reactivate interoceptive aversive memory, participants will be asked to breathe a medical grade 35% CO2/65% O2 gas mixture which produces somatic perturbations. The 35% CO2 challenge is a widely used and safe symptom induction technique that has been utilized in our laboratory in several experiments. Participants will be informed that breathing the gas is safe, but that it will likely cause changes in their physical sensations. Participants will specifically be asked to breathe the gas mixture normally with their mouth open through an oxygen mask for 10 seconds.
Study NCT04726475 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol (CBD)-Rich Broad Spectrum Hemp Extract Oil
Description: 300mg CBD-rich hemp-derived formulation in MCT coconut oil.
Study NCT04726475 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD)-Rich Broad Spectrum Hemp Extract Oil
Description: 300mg CBD-rich hemp-derived formulation in MCT coconut oil.
Study NCT04726475 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oil
Description: 3ml oral dose of MCT coconut oil.
Study NCT05410236 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D bronchial tree model
Description: A detachable 3D printed bronchial tree model
Study NCT05183217 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online Continence promotion program without tailoring
Description: The online continence promotion program has five sections (Introduction, Exercise, Bladder, Bowels, Care Seeking) that build knowledge, self-efficacy, and skills to set action and coping plans relevant to a participant's symptoms. This online program is based on an in-person, small-group program that has demonstrated effectiveness to improve both urinary and bowel incontinence in women age 50 and above. Participants will receive automated weekly reminders reminding them to re-visit the program, regardless of their individual user activity.
Study NCT05183217 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Continence promotion program with tailoring
Description: The online continence promotion program has five sections (Introduction, Exercise, Bladder, Bowels, Care Seeking) that build knowledge, self-efficacy, and skills to set action and coping plans relevant to a participant's symptoms. This online program is based on an in-person, small-group program that has demonstrated effectiveness to improve both urinary and bowel incontinence in women age 50 and above. Participants will receive tailored output (personalized cues, emphasis on relevant content, individualized and tailored reminders about their goals) based on a computer algorithm incorporating unique user inputs (individual factors). Inputs will be reassessed every 2 weeks for retailoring so that personalization evolves over the course of the intervention.
Study NCT05466994 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: IPAD
Description: Participant will play a game through (standard camera) participants will be able to the hospital room and decals as they appear in the real world
Study NCT05466994 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Augmented Reality
Description: Participants will play a game through (devices camera and application) let us participants view the real world
Study NCT06395298 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental group PIOMI
Description: A group treated with the application of the care model Newborn Individualized Development Care and Assessment Program (NIDCAP) in the Neonatal Intensive Unit Care (NICU)+PIOMI
Study NCT06395298 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control group NIDCAP
Description: A group treated with the application of the care model Newborn Individualized Development Care and Assessment Program (NIDCAP) in the Neonatal Intensive Unit Care (NICU)
Study NCT06056882 — intervention group
Intervention type: OTHER
Intervention: CLE-guided cryobiopsy
Description: During bronchoscopy, that is performed for suspicious pulmonary lesions, it is planned to use the CLE probe and cryoprobe simultaneously wafter detection of the round focus.
Study NCT05603195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN7508 (IV)
Description: Administered sequential, ascending single intravenous (IV) dose
Study NCT04950049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: receive 2ml dexamethasone (5mg/ml)
Study NCT04950049 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diluted dexamethasone 5ml
Description: receive 5ml dexamethasone (2mg/ml) diluted with 5% glucose
Study NCT05603195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN7508 (SC)
Description: Administered sequential, ascending single subcutaneous (SC) dose
Study NCT05603195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo (IV)
Description: Administered sequential, ascending single intravenous (IV) dose
Study NCT05603195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo (SC)
Description: Administered sequential, ascending single subcutaneous (SC) dose
Study NCT05888441 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Obstacle characteristics
Description: In the walking trials, when an obstacle is present, the obstacle height and obstacle contrast level will be varied across the trial repetitions.~Each participant will be exposed to obstacles of two heights: the first will be 1 centimeter in height, and the second will be approximately 20% of the subject's leg length (ranging in physical height between 15 - 22 centimeters to cover a range of leg lengths in the population).~Obstacles (of both heights) will also be painted such that their measured luminance (or contrast) level against the floor luminance is varied. High contrast obstacles will have ≥80% Michelson contrast and low contrast obstacles will have ≤30% Michelson contrast.
Study NCT05888441 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Obstacle characteristics
Description: In the walking trials, when an obstacle is present, the obstacle height and obstacle contrast level will be varied across the trial repetitions.~Each participant will be exposed to obstacles of two heights: the first will be 1 centimeter in height, and the second will be approximately 20% of the subject's leg length (ranging in physical height between 15 - 22 centimeters to cover a range of leg lengths in the population).~Obstacles (of both heights) will also be painted such that their measured luminance (or contrast) level against the floor luminance is varied. High contrast obstacles will have ≥80% Michelson contrast and low contrast obstacles will have ≤30% Michelson contrast.
Study NCT05546346 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: wearable magnet tracking system
Description: In this group, wearable magnet tracking system was used.
Study NCT05477485 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: AIMS program - patient
Description: Patient-level support will be offered to eligible Virginia Medicaid enrollees who have a late ART prescription refill(s) by >30 days. Support will come from the provider, pharmacy, managed care organization or the community. Patient-level support will involve direct linkages and referrals for participants with a late ART prescription refill(s) >30-60 days. Support will intensify as the gap in ART prescription(s) fills increases. For those with a late ART prescription refill(s) for >60 days, added patient-level support will include warm health technology via PositiveLinks, a mobile app program promoting better health through self-monitoring tools, educational resources, direct messaging with program staff and a confidential user community board.